New drug combo aims to boost immune attack on kidney tumors before surgery
NCT ID NCT07516366
First seen Apr 19, 2026 · Last updated Jun 22, 2026 · Updated 9 times
Summary
This phase II trial is testing whether giving two immunotherapy drugs, botensilimab and balstilimab, before surgery is safe and feasible for people with high-risk clear cell kidney cancer that hasn't spread. The 16 participants will receive the drugs before their kidney removal surgery. The main goals are to see if most patients can complete treatment and have surgery on time, and to check for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IV RENAL CELL CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
botensilimab and balstilimab (immunotherapy drugs)
What this could lead to
If successful, this could show that giving these two immunotherapy drugs before surgery helps shrink kidney tumors and improves outcomes for high-risk patients.
What could go wrong
This is a small, early-phase trial with only 16 participants. The drugs may cause side effects, and the combination might not work as hoped. Results may not apply to all kidney cancer patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.